시장조사 보고서 : 세계의 고지혈증 처방약 시장예측 2021년-2026년

■ 영문 제목 : Global Hyperlipidemia Prescription Drugs Market Growth 2021-2026
	■ 상품코드 : LPI-2108K201466 ■ 조사/발행회사 : LP Information ■ 발행일 : 2021년 8월 (※2025년 최신판이 있습니다. 문의 주세요.) ■ 페이지수 : 133 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 의약품

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1명 열람용)	USD3,660 ⇒환산￦5,124,000	견적의뢰/주문/질문
Multi User (20명 열람용)	USD5,490 ⇒환산￦7,686,000	견적의뢰/주문/질문
Corporate User (동일기업내 공유가능)	USD7,320 ⇒환산￦10,248,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

본 조사보고서는 고지혈증 처방약의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아, 러시아, 중동/아프리카, 이집트, 남아프리카, 터키, 중동GCC국 등), 시장동향, 판매/유통업자/고객 리스트, 시장예측 (2021년-2026년), 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익) 등의 정보를 포함하고 있습니다. 또한, 주요지역의 종류별 시장규모 (HMG COA 환원효소 억제제, 섬유산 유도체, 니코틴산, 담즙산 격리제, 콜레스테롤 흡수 억제제, 복합 약물 요법)와 용도별 시장규모 (병원, 진료소) 데이터도 수록되어 있습니다.
- 조사 범위
- 경영자용 요약
- 기업별 고지혈증 처방약 시장 점유율
- 지역별 고지혈증 처방약 시장규모
- 주요지역의 종류별 시장규모 (HMG COA 환원효소 억제제, 섬유산 유도체, 니코틴산, 담즙산 격리제, 콜레스테롤 흡수 억제제, 복합 약물 요법)
- 주요지역의 용도별 시장규모 (병원, 진료소)
- 미주의 고지혈증 처방약 시장규모 (미국, 캐나다, 멕시코, 브라질 등)
- 아시아의 고지혈증 처방약 시장규모 (중국, 일본, 한국, 동남아시아, 인도 등)
- 유럽의 고지혈증 처방약 시장규모 (독일, 프랑스, 영국, 이탈리아, 러시아 등)
- 중동/아프리카의 고지혈증 처방약 시장규모 (이집트, 남아프리카, 터키, 중동GCC지역 등)
- 시장의 성장요인, 과제, 동향
- 마케팅, 유통업자, 고객리스트
- 세계의 고지혈증 처방약 시장예측 (2021년-2026년)
- 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익)
- 조사의 결과/결론

■ 보고서 개요

According to this latest study, the 2020 growth of Hyperlipidemia Prescription Drugs will have significant change from previous year. By the most conservative estimates of global Hyperlipidemia Prescription Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Hyperlipidemia Prescription Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Hyperlipidemia Prescription Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
HMG COA Reductase Inhibitors
Fibric Acid Derivatives
Nicotinic Acid
Bile Acid Sequestrating Agents
Cholesterol Absorption Inhibitors
Combination Drug Therapy

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Hospital
Clinic

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Amgen
Eli Lilly
GlaxoSmithKline Pharmaceuticals
Isis Pharmaceuticals
Merck
Dr.Reddy’s Laboratories
Immuron Limited
Esperion Therapeutics
Pfizer
Formac Pharmaceuticals

■ 보고서 목차

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hyperlipidemia Prescription Drugs Consumption 2016-2026
2.1.2 Hyperlipidemia Prescription Drugs Consumption CAGR by Region
2.2 Hyperlipidemia Prescription Drugs Segment by Type
2.2.1 HMG COA Reductase Inhibitors
2.2.2 Fibric Acid Derivatives
2.2.3 Nicotinic Acid
2.2.4 Bile Acid Sequestrating Agents
2.2.5 Cholesterol Absorption Inhibitors
2.2.6 Combination Drug Therapy
2.3 Hyperlipidemia Prescription Drugs Sales by Type
2.3.1 Global Hyperlipidemia Prescription Drugs Sales Market Share by Type (2016-2021)
2.3.2 Global Hyperlipidemia Prescription Drugs Revenue and Market Share by Type (2016-2021)
2.3.3 Global Hyperlipidemia Prescription Drugs Sale Price by Type (2016-2021)
2.4 Hyperlipidemia Prescription Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Hyperlipidemia Prescription Drugs Sales by Application
2.5.1 Global Hyperlipidemia Prescription Drugs Sale Market Share by Application (2016-2021)
2.5.2 Global Hyperlipidemia Prescription Drugs Revenue and Market Share by Application (2016-2021)
2.5.3 Global Hyperlipidemia Prescription Drugs Sale Price by Application (2016-2021)

3 Global Hyperlipidemia Prescription Drugs by Company
3.1 Global Hyperlipidemia Prescription Drugs Sales Market Share by Company
3.1.1 Global Hyperlipidemia Prescription Drugs Sales by Company (2019-2021)
3.1.2 Global Hyperlipidemia Prescription Drugs Sales Market Share by Company (2019-2021)
3.2 Global Hyperlipidemia Prescription Drugs Revenue Market Share by Company
3.2.1 Global Hyperlipidemia Prescription Drugs Revenue by Company (2019-2021)
3.2.2 Global Hyperlipidemia Prescription Drugs Revenue Market Share by Company (2019-2021)
3.3 Global Hyperlipidemia Prescription Drugs Sale Price by Company
3.4 Global Manufacturers Hyperlipidemia Prescription Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hyperlipidemia Prescription Drugs Product Location Distribution
3.4.2 Players Hyperlipidemia Prescription Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Hyperlipidemia Prescription Drugs by Region
4.1 Global Hyperlipidemia Prescription Drugs by Region
4.1.1 Global Hyperlipidemia Prescription Drugs Sales by Region
4.1.2 Global Hyperlipidemia Prescription Drugs Revenue by Region
4.2 Americas Hyperlipidemia Prescription Drugs Sales Growth
4.3 APAC Hyperlipidemia Prescription Drugs Sales Growth
4.4 Europe Hyperlipidemia Prescription Drugs Sales Growth
4.5 Middle East & Africa Hyperlipidemia Prescription Drugs Sales Growth

5 Americas
5.1 Americas Hyperlipidemia Prescription Drugs Sales by Country
5.1.1 Americas Hyperlipidemia Prescription Drugs Sales by Country (2016-2021)
5.1.2 Americas Hyperlipidemia Prescription Drugs Revenue by Country (2016-2021)
5.2 Americas Hyperlipidemia Prescription Drugs Sales by Type
5.3 Americas Hyperlipidemia Prescription Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Hyperlipidemia Prescription Drugs Sales by Region
6.1.1 APAC Hyperlipidemia Prescription Drugs Sales by Region (2016-2021)
6.1.2 APAC Hyperlipidemia Prescription Drugs Revenue by Region (2016-2021)
6.2 APAC Hyperlipidemia Prescription Drugs Sales by Type
6.3 APAC Hyperlipidemia Prescription Drugs Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Hyperlipidemia Prescription Drugs by Country
7.1.1 Europe Hyperlipidemia Prescription Drugs Sales by Country (2016-2021)
7.1.2 Europe Hyperlipidemia Prescription Drugs Revenue by Country (2016-2021)
7.2 Europe Hyperlipidemia Prescription Drugs Sales by Type
7.3 Europe Hyperlipidemia Prescription Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Hyperlipidemia Prescription Drugs by Country
8.1.1 Middle East & Africa Hyperlipidemia Prescription Drugs Sales by Country (2016-2021)
8.1.2 Middle East & Africa Hyperlipidemia Prescription Drugs Revenue by Country (2016-2021)
8.2 Middle East & Africa Hyperlipidemia Prescription Drugs Sales by Type
8.3 Middle East & Africa Hyperlipidemia Prescription Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Hyperlipidemia Prescription Drugs Distributors
10.3 Hyperlipidemia Prescription Drugs Customer

11 Global Hyperlipidemia Prescription Drugs Market Forecast
11.1 Global Hyperlipidemia Prescription Drugs Forecast by Region
11.1.1 Global Hyperlipidemia Prescription Drugs Forecast by Regions (2021-2026)
11.2.2 Global Hyperlipidemia Prescription Drugs Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Countries
11.3 APAC Forecast by Region
11.4 Europe Forecast by Countries
11.5 Middle East & Africa Forecast by Countries
11.6 Global Hyperlipidemia Prescription Drugs Forecast by Type
11.7 Global Hyperlipidemia Prescription Drugs Forecast by Application

12 Key Players Analysis
12.1 Amgen
12.1.1 Amgen Amgen Company Information
12.1.2 Amgen Hyperlipidemia Prescription Drugs Product Offered
12.1.3 Amgen Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Amgen Main Business Overview
12.1.5 Amgen Latest Developments
12.2 Eli Lilly
12.2.1 Eli Lilly Company Information
12.2.2 Eli Lilly Hyperlipidemia Prescription Drugs Product Offered
12.2.3 Eli Lilly Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Eli Lilly Main Business Overview
12.2.5 Eli Lilly Latest Developments
12.3 GlaxoSmithKline Pharmaceuticals
12.3.1 GlaxoSmithKline Pharmaceuticals Company Information
12.3.2 GlaxoSmithKline Pharmaceuticals Hyperlipidemia Prescription Drugs Product Offered
12.3.3 GlaxoSmithKline Pharmaceuticals Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 GlaxoSmithKline Pharmaceuticals Main Business Overview
12.3.5 GlaxoSmithKline Pharmaceuticals Latest Developments
12.4 Isis Pharmaceuticals
12.4.1 Isis Pharmaceuticals Company Information
12.4.2 Isis Pharmaceuticals Hyperlipidemia Prescription Drugs Product Offered
12.4.3 Isis Pharmaceuticals Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Isis Pharmaceuticals Main Business Overview
12.4.5 Isis Pharmaceuticals Latest Developments
12.5 Merck
12.5.1 Merck Company Information
12.5.2 Merck Hyperlipidemia Prescription Drugs Product Offered
12.5.3 Merck Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Merck Main Business Overview
12.5.5 Merck Latest Developments
12.6 Dr.Reddy’s Laboratories
12.6.1 Dr.Reddy’s Laboratories Company Information
12.6.2 Dr.Reddy’s Laboratories Hyperlipidemia Prescription Drugs Product Offered
12.6.3 Dr.Reddy’s Laboratories Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Dr.Reddy’s Laboratories Main Business Overview
12.6.5 Dr.Reddy’s Laboratories Latest Developments
12.7 Immuron Limited
12.7.1 Immuron Limited Company Information
12.7.2 Immuron Limited Hyperlipidemia Prescription Drugs Product Offered
12.7.3 Immuron Limited Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Immuron Limited Main Business Overview
12.7.5 Immuron Limited Latest Developments
12.8 Esperion Therapeutics
12.8.1 Esperion Therapeutics Company Information
12.8.2 Esperion Therapeutics Hyperlipidemia Prescription Drugs Product Offered
12.8.3 Esperion Therapeutics Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 Esperion Therapeutics Main Business Overview
12.8.5 Esperion Therapeutics Latest Developments
12.9 Pfizer
12.9.1 Pfizer Company Information
12.9.2 Pfizer Hyperlipidemia Prescription Drugs Product Offered
12.9.3 Pfizer Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.9.4 Pfizer Main Business Overview
12.9.5 Pfizer Latest Developments
12.10 Formac Pharmaceuticals
12.10.1 Formac Pharmaceuticals Company Information
12.10.2 Formac Pharmaceuticals Hyperlipidemia Prescription Drugs Product Offered
12.10.3 Formac Pharmaceuticals Hyperlipidemia Prescription Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.10.4 Formac Pharmaceuticals Main Business Overview
12.10.5 Formac Pharmaceuticals Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Hyperlipidemia Prescription Drugs Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of HMG COA Reductase Inhibitors
Table 3. Major Players of Fibric Acid Derivatives
Table 4. Major Players of Nicotinic Acid
Table 5. Major Players of Bile Acid Sequestrating Agents
Table 6. Major Players of Cholesterol Absorption Inhibitors
Table 7. Major Players of Combination Drug Therapy
Table 8. Global Hyperlipidemia Prescription Drugs Sales by Type (2016-2021) & (K Units)
Table 9. Global Hyperlipidemia Prescription Drugs Sales Market Share by Type (2016-2021)
Table 10. Global Hyperlipidemia Prescription Drugs Revenue by Type (2016-2021) & ($ million)
Table 11. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Type (2016-2021)
Table 12. Global Hyperlipidemia Prescription Drugs Sale Price by Type (2016-2021)
Table 13. Global Hyperlipidemia Prescription Drugs Sales by Application (2016-2021) & (K Units)
Table 14. Global Hyperlipidemia Prescription Drugs Sales Market Share by Application (2016-2021)
Table 15. Global Hyperlipidemia Prescription Drugs Value by Application (2016-2021)
Table 16. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Application (2016-2021)
Table 17. Global Hyperlipidemia Prescription Drugs Sale Price by Application (2016-2021)
Table 18. Global Hyperlipidemia Prescription Drugs Sales by Company (2019-2021) & (K Units)
Table 19. Global Hyperlipidemia Prescription Drugs Sales Market Share by Company (2019-2021)
Table 20. Global Hyperlipidemia Prescription Drugs Revenue by Company (2019-2021) ($ Millions)
Table 21. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Company (2019-2021)
Table 22. Global Hyperlipidemia Prescription Drugs Sale Price by Company (2019-2021)
Table 23. Key Manufacturers Hyperlipidemia Prescription Drugs Producing Area Distribution and Sales Area
Table 24. Players Hyperlipidemia Prescription Drugs Products Offered
Table 25. Hyperlipidemia Prescription Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Hyperlipidemia Prescription Drugs Sales by Region (2016-2021) (K Units)
Table 29. Global Hyperlipidemia Prescription Drugs Sales Market Share by Region (2016-2021)
Table 30. Global Hyperlipidemia Prescription Drugs Revenue by Region (2016-2021) & ($ Millions)
Table 31. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Region (2016-2021)
Table 32. Americas Hyperlipidemia Prescription Drugs Sales by Country (2016-2021) & (K Units)
Table 33. Americas Hyperlipidemia Prescription Drugs Sales Market Share by Country (2016-2021)
Table 34. Americas Hyperlipidemia Prescription Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 35. Americas Hyperlipidemia Prescription Drugs Revenue Market Share by Country (2016-2021)
Table 36. Americas Hyperlipidemia Prescription Drugs Sales by Type (2016-2021) & (K Units)
Table 37. Americas Hyperlipidemia Prescription Drugs Sales Market Share by Type (2016-2021)
Table 38. Americas Hyperlipidemia Prescription Drugs Sales by Application (2016-2021) & (K Units)
Table 39. Americas Hyperlipidemia Prescription Drugs Sales Market Share by Application (2016-2021)
Table 40. APAC Hyperlipidemia Prescription Drugs Sales by Region (2016-2021) & (K Units)
Table 41. APAC Hyperlipidemia Prescription Drugs Sales Market Share by Region (2016-2021)
Table 42. APAC Hyperlipidemia Prescription Drugs Revenue by Region (2016-2021) & ($ Millions)
Table 43. APAC Hyperlipidemia Prescription Drugs Revenue Market Share by Region (2016-2021)
Table 44. APAC Hyperlipidemia Prescription Drugs Sales by Type (2016-2021) & (K Units)
Table 45. APAC Hyperlipidemia Prescription Drugs Sales Market Share by Type (2016-2021)
Table 46. APAC Hyperlipidemia Prescription Drugs Sales by Application (2016-2021) & (K Units)
Table 47. APAC Hyperlipidemia Prescription Drugs Sales Market Share by Application (2016-2021)
Table 48. Europe Hyperlipidemia Prescription Drugs Sales by Country (2016-2021) & (K Units)
Table 49. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Country (2016-2021)
Table 50. Europe Hyperlipidemia Prescription Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 51. Europe Hyperlipidemia Prescription Drugs Revenue Market Share by Country (2016-2021)
Table 52. Europe Hyperlipidemia Prescription Drugs Sales by Type (2016-2021) & (K Units)
Table 53. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Type (2016-2021)
Table 54. Europe Hyperlipidemia Prescription Drugs Sales by Application (2016-2021) & (K Units)
Table 55. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Application (2016-2021)
Table 56. Middle East & Africa Hyperlipidemia Prescription Drugs Sales by Country (2016-2021) & (K Units)
Table 57. Middle East & Africa Hyperlipidemia Prescription Drugs Sales Market Share by Country (2016-2021)
Table 58. Middle East & Africa Hyperlipidemia Prescription Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 59. Middle East & Africa Hyperlipidemia Prescription Drugs Revenue Market Share by Country (2016-2021)
Table 60. Middle East & Africa Hyperlipidemia Prescription Drugs Sales by Type (2016-2021) & (K Units)
Table 61. Middle East & Africa Hyperlipidemia Prescription Drugs Sales Market Share by Type (2016-2021)
Table 62. Middle East & Africa Hyperlipidemia Prescription Drugs Sales by Application (2016-2021) & (K Units)
Table 63. Middle East & Africa Hyperlipidemia Prescription Drugs Sales Market Share by Application (2016-2021)
Table 64. Global Hyperlipidemia Prescription Drugs Sales Forecast by Type (2021-2026) & (K Units)
Table 65. Global Hyperlipidemia Prescription Drugs Sales Market Share Forecast by Type (2021-2026)
Table 66. Global Hyperlipidemia Prescription Drugs Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 67. Global Hyperlipidemia Prescription Drugs Revenue Market Share Forecast by Type (2021-2026)
Table 68. Global Hyperlipidemia Prescription Drugs Sales Forecast by Application (2021-2026) & (K Units)
Table 69. Global Hyperlipidemia Prescription Drugs Sales Market Share Forecast by Application (2021-2026)
Table 70. Global Hyperlipidemia Prescription Drugs Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 71. Global Hyperlipidemia Prescription Drugs Revenue Market Share Forecast by Application (2021-2026)
Table 72. Amgen Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. Amgen Hyperlipidemia Prescription Drugs Product Offered
Table 74. Amgen Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 75. Amgen Main Business
Table 76. Amgen Latest Developments
Table 77. Eli Lilly Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Eli Lilly Hyperlipidemia Prescription Drugs Product Offered
Table 79. Eli Lilly Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 80. Eli Lilly Main Business
Table 81. Eli Lilly Latest Developments
Table 82. GlaxoSmithKline Pharmaceuticals Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. GlaxoSmithKline Pharmaceuticals Hyperlipidemia Prescription Drugs Product Offered
Table 84. GlaxoSmithKline Pharmaceuticals Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 85. GlaxoSmithKline Pharmaceuticals Main Business
Table 86. GlaxoSmithKline Pharmaceuticals Latest Developments
Table 87. Isis Pharmaceuticals Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Isis Pharmaceuticals Hyperlipidemia Prescription Drugs Product Offered
Table 89. Isis Pharmaceuticals Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 90. Isis Pharmaceuticals Main Business
Table 91. Isis Pharmaceuticals Latest Developments
Table 92. Merck Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck Hyperlipidemia Prescription Drugs Product Offered
Table 94. Merck Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 95. Merck Main Business
Table 96. Merck Latest Developments
Table 97. Dr.Reddy's Laboratories Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Dr.Reddy's Laboratories Hyperlipidemia Prescription Drugs Product Offered
Table 99. Dr.Reddy's Laboratories Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 100. Dr.Reddy's Laboratories Main Business
Table 101. Dr.Reddy's Laboratories Latest Developments
Table 102. Immuron Limited Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Immuron Limited Hyperlipidemia Prescription Drugs Product Offered
Table 104. Immuron Limited Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 105. Immuron Limited Main Business
Table 106. Immuron Limited Latest Developments
Table 107. Esperion Therapeutics Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Esperion Therapeutics Hyperlipidemia Prescription Drugs Product Offered
Table 109. Esperion Therapeutics Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 110. Esperion Therapeutics Main Business
Table 111. Esperion Therapeutics Latest Developments
Table 112. Pfizer Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Pfizer Hyperlipidemia Prescription Drugs Product Offered
Table 114. Pfizer Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 115. Pfizer Main Business
Table 116. Pfizer Latest Developments
Table 117. Formac Pharmaceuticals Basic Information, Hyperlipidemia Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Formac Pharmaceuticals Hyperlipidemia Prescription Drugs Product Offered
Table 119. Formac Pharmaceuticals Hyperlipidemia Prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2021E)
Table 120. Formac Pharmaceuticals Main Business
Table 121. Formac Pharmaceuticals Latest Developments
List of Figures
Figure 1. Picture of Hyperlipidemia Prescription Drugs
Figure 2. Hyperlipidemia Prescription Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Hyperlipidemia Prescription Drugs Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global Hyperlipidemia Prescription Drugs Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Hyperlipidemia Prescription Drugs Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of HMG COA Reductase Inhibitors
Figure 10. Product Picture of Fibric Acid Derivatives
Figure 11. Product Picture of Nicotinic Acid
Figure 12. Product Picture of Bile Acid Sequestrating Agents
Figure 13. Product Picture of Cholesterol Absorption Inhibitors
Figure 14. Product Picture of Combination Drug Therapy
Figure 15. Global Hyperlipidemia Prescription Drugs Sales Market Share by Type in 2020
Figure 16. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Type (2016-2021)
Figure 17. Hyperlipidemia Prescription Drugs Consumed in Hospital
Figure 18. Global Hyperlipidemia Prescription Drugs Market: Hospital (2016-2021) & (K Units)
Figure 19. Hyperlipidemia Prescription Drugs Consumed in Clinic
Figure 20. Global Hyperlipidemia Prescription Drugs Market: Clinic (2016-2021) & (K Units)
Figure 21. Global Hyperlipidemia Prescription Drugs Sales Market Share by Application (2016-2021)
Figure 22. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Application in 2020
Figure 23. Global Hyperlipidemia Prescription Drugs Revenue Market by Company in 2020 ($ Million)
Figure 24. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Company in 2020
Figure 25. Global Hyperlipidemia Prescription Drugs Sales Market Share by Regions (2016-2021)
Figure 26. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Region in 2020
Figure 27. Americas Hyperlipidemia Prescription Drugs Sales 2016-2021 (K Units)
Figure 28. Americas Hyperlipidemia Prescription Drugs Revenue 2016-2021 ($ Millions)
Figure 29. APAC Hyperlipidemia Prescription Drugs Sales 2016-2021 (K Units)
Figure 30. APAC Hyperlipidemia Prescription Drugs Revenue 2016-2021 ($ Millions)
Figure 31. Europe Hyperlipidemia Prescription Drugs Sales 2016-2021 (K Units)
Figure 32. Europe Hyperlipidemia Prescription Drugs Revenue 2016-2021 ($ Millions)
Figure 33. Middle East & Africa Hyperlipidemia Prescription Drugs Sales 2016-2021 (K Units)
Figure 34. Middle East & Africa Hyperlipidemia Prescription Drugs Revenue 2016-2021 ($ Millions)
Figure 35. Americas Hyperlipidemia Prescription Drugs Sales Market Share by Country in 2020
Figure 36. Americas Hyperlipidemia Prescription Drugs Revenue Market Share by Country in 2020
Figure 37. Americas Hyperlipidemia Prescription Drugs Sales Market Share by Type in 2020
Figure 38. Americas Hyperlipidemia Prescription Drugs Sales Market Share by Application in 2020
Figure 39. United States Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 40. Canada Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 41. Mexico Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 42. Brazil Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 43. APAC Hyperlipidemia Prescription Drugs Sales Market Share by Region in 2020
Figure 44. APAC Hyperlipidemia Prescription Drugs Revenue Market Share by Regions in 2020
Figure 45. APAC Hyperlipidemia Prescription Drugs Sales Market Share by Type in 2020
Figure 46. APAC Hyperlipidemia Prescription Drugs Sales Market Share by Application in 2020
Figure 47. China Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 48. Japan Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 49. Korea Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 50. Southeast Asia Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 51. India Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 52. Australia Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 53. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Country in 2020
Figure 54. Europe Hyperlipidemia Prescription Drugs Revenue Market Share by Country in 2020
Figure 55. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Type in 2020
Figure 56. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Application in 2020
Figure 57. Germany Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 58. France Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 59. UK Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 60. Italy Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 61. Russia Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 62. Middle East & Africa Hyperlipidemia Prescription Drugs Sales Market Share by Country in 2020
Figure 63. Middle East & Africa Hyperlipidemia Prescription Drugs Revenue Market Share by Country in 2020
Figure 64. Middle East & Africa Hyperlipidemia Prescription Drugs Sales Market Share by Type in 2020
Figure 65. Middle East & Africa Hyperlipidemia Prescription Drugs Sales Market Share by Application in 2020
Figure 66. Egypt Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 67. South Africa Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 68. Israel Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 69. Turkey Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 70. GCC Country Hyperlipidemia Prescription Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 71. Channels of Distribution
Figure 72. Distributors Profiles

※본 조사보고서 [세계의 고지혈증 처방약 시장예측 2021년-2026년] (코드 : LPI-2108K201466) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 고지혈증 처방약 시장예측 2021년-2026년] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 자료도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

세계의 항비만약 시장예측 2021년-2026년
LPI-2108K200019 / LP Information / 2021년 8월 / 본 조사보고서는 항비만약의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아, 러시아,...According to this latest study, the 2020 growth of Anti Obesity Drugs will have significant change from previous year. By the most conservative estimates of global Anti Obesity Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in...

세계의 감량 치료제 시장예측 2021년-2026년
LPI-2108K200004 / LP Information / 2021년 8월 / 본 조사보고서는 감량 치료제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아,...According to this latest study, the 2020 growth of Weight Loss Drugs will have significant change from previous year. By the most conservative estimates of global Weight Loss Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in...

세계의 항소화성 궤양 치료약 시장예측 2021년-2026년
LPI-2108K201064 / LP Information / 2021년 8월 / 본 조사보고서는 항소화성 궤양 치료약의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2020 growth of Anti Peptic Ulcer Drugs will have significant change from previous year. By the most conservative estimates of global Anti Peptic Ulcer Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx...

세계의 정신 장애 치료약 시장예측 2021년-2026년
LPI-2108K201578 / LP Information / 2021년 8월 / 본 조사보고서는 정신 장애 치료약의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2020 growth of Mental Disorders Drugs will have significant change from previous year. By the most conservative estimates of global Mental Disorders Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in...

세계의 당뇨병 치료약 시장예측 2021년-2026년
LPI-2108K202104 / LP Information / 2021년 8월 / 본 조사보고서는 당뇨병 치료약의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아,...According to this latest study, the 2020 growth of Antidiabetic Drugs will have significant change from previous year. By the most conservative estimates of global Antidiabetic Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over...

세계의 양극성 장애 약물 시장예측 2021년-2026년
LPI-2108K202119 / LP Information / 2021년 8월 / 본 조사보고서는 양극성 장애 약물의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2020 growth of Bipolar Disorder Drugs will have significant change from previous year. By the most conservative estimates of global Bipolar Disorder Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in...

세계의 항우울제 시장예측 2021년-2026년
LPI-2108K202103 / LP Information / 2021년 8월 / 본 조사보고서는 항우울제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아, 러시아,...According to this latest study, the 2020 growth of Antidepressant Drugs will have significant change from previous year. By the most conservative estimates of global Antidepressant Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 12180 million in 2019. Over...

세계의 생물학적 치료제 시장예측 2021년-2026년
LPI-2108K202118 / LP Information / 2021년 8월 / 본 조사보고서는 생물학적 치료제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아,...According to this latest study, the 2020 growth of Biologic Therapeutics Drugs will have significant change from previous year. By the most conservative estimates of global Biologic Therapeutics Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 315410 million in...

세계의 입술 포진용 치료약 시장예측 2021년-2026년
LPI-2108K200023 / LP Information / 2021년 8월 / 본 조사보고서는 입술 포진용 치료약의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2020 growth of Herpes Labialis Drugs will have significant change from previous year. By the most conservative estimates of global Herpes Labialis Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in...

세계의 동물용 통증 관리약 시장예측 2021년-2026년
LPI-2108K201967 / LP Information / 2021년 8월 / 본 조사보고서는 동물용 통증 관리약의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2020 growth of Veterinary Pain Management Drugs will have significant change from previous year. By the most conservative estimates of global Veterinary Pain Management Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx...